Japanese Start-Up Gets Fast-Track Status For Flu Vaccine
This article was originally published in PharmAsia News
Executive Summary
Japan's Health Ministry has granted fast-track status to a startup drug maker's application to begin human trials on a flu vaccine. The UMN-0501 vaccine was developed by UMN Pharma, which mass produced it in cultures of cells rather than using chicken eggs. The new process allows for an eight-week turnaround. UMN could be ready to submit its drug as early as 2010 under the ministry's orphan drug system. (Click here for more - a subscription may be required
Japan's Health Ministry has granted fast-track status to a startup drug maker's application to begin human trials on a flu vaccine. The UMN-0501 vaccine was developed by UMN Pharma, which mass produced it in cultures of cells rather than using chicken eggs. The new process allows for an eight-week turnaround. UMN could be ready to submit its drug as early as 2010 under the ministry's orphan drug system. (Click here for more - a subscription may be required) "Pharmaceutical Start-Up Wins Fast-Track Status For Flu Vaccine" - Nikkei (Japan) (6/11/08) |